Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
Dow Jones Industrial Average
Nasdaq Composite
Standard & Poors 500
New York Composite
Gold
Crude Oil
Markets
Stocks
Funds
Tools
Overview
News
Currencies
International
Treasuries
Atara Biotherap
(NQ:
ATRA
)
18.72
USD
+0.11 (+0.59%)
Streaming Delayed Price
Updated: 7:00 AM EST, Jan 19, 2021
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press releases about Atara Biotherap
< Previous
1
2
3
4
5
6
7
Next >
Atara Bio Announces Collaborating Investigators to Present Data from a Late Breaking Abstract at the American Association for Cancer Research (AACR) Annual Meeting
March 16, 2016
Presentation to Report Clinical Trial Results in Nasopharyngeal Cancer
From
GlobeNewswire News Releases
Atara Bio Announces Fourth Quarter and Full Year 2015 Financial Results and Recent Highlights
March 03, 2016
Atara Biotherapeutics, Inc. (Nasdaq:ATRA), a biopharmaceutical company focused on developing meaningful therapies for patients with severe and life-threatening diseases that have been underserved by...
From
GlobeNewswire News Releases
Atara Bio to Present at the Cowen and Company 36th Annual Health Care Conference
February 29, 2016
Atara Biotherapeutics, Inc. (Nasdaq:ATRA), a biopharmaceutical company focused on developing meaningful therapies for patients with severe and life-threatening diseases that have been underserved by...
From
GlobeNewswire News Releases
Atara Bio Receives FDA Orphan Drug Designation for EBV-CTL to Treat Epstein-Barr Virus-Associated Post-Transplant Lymphoproliferative Disorder (EBV-PTLD)
February 08, 2016
Atara Biotherapeutics, Inc. (Nasdaq:ATRA), a biopharmaceutical company focused on developing meaningful therapies for patients with severe and life-threatening diseases that have been underserved by...
From
GlobeNewswire News Releases
Atara Bio Announces Participation in Two Upcoming Investor Conferences
January 27, 2016
Atara Biotherapeutics, Inc. (Nasdaq:ATRA), a biopharmaceutical company focused on developing meaningful therapies for patients with unmet medical needs in diseases that have seen limited therapeutic...
From
GlobeNewswire News Releases
Atara Biotherapeutics Inc (NASDAQ:ATRA) Shareholder Alert: Investigation Announced
January 26, 2016
San Diego, CA -- (SBWIRE) -- 01/26/2016 -- An investigation for shareholders in Atara Biotherapeutics Inc (NASDAQ:ATRA) shares over potential securities laws violations was announced.
From
SBWire - Latest Press Releases
Atara Bio to Present at the 34th Annual J.P. Morgan Healthcare Conference
January 04, 2016
Atara Biotherapeutics, Inc. (Nasdaq:ATRA), a biopharmaceutical company focused on developing meaningful therapies for patients with unmet medical needs in diseases that have seen limited therapeutic...
From
GlobeNewswire News Releases
Atara Bio Added to the NASDAQ Biotechnology Index
December 18, 2015
Atara Biotherapeutics, Inc. (Nasdaq:ATRA), a biopharmaceutical company focused on developing meaningful therapies for patients with unmet medical needs in diseases that have seen limited therapeutic...
From
GlobeNewswire News Releases
Atara Bio Announces Results From the Phase 2 Proof-of-Concept PINTA 745 Clinical Trial for Protein Energy Wasting in Patients With End Stage Renal Disease
December 13, 2015
Atara Bio to Host Conference Call and Webcast Today at 8:00 a.m. Eastern Time
From
GlobeNewswire News Releases
Atara Bio Announces Positive Results From a Phase 2 Clinical Trial of Cytomegalovirus Targeted Cytotoxic T Lymphocytes (CMV-CTL), a Novel Approach to Adoptive Immunotherapy, to Treat Patients With Ref
December 06, 2015
Atara Biotherapeutics, Inc. (Nasdaq:ATRA), a biopharmaceutical company focused on developing meaningful therapies for patients with unmet medical needs in diseases that have seen limited therapeutic...
From
GlobeNewswire News Releases
Atara Bio Announces Positive Results From Phase 1 Clinical Trial of Wilms’ Tumor 1 Targeted Cytotoxic T Lymphocytes (WT1-CTL) Product Candidate in Hematologic Malignancies
December 05, 2015
Atara Biotherapeutics, Inc. (Nasdaq:ATRA), a biopharmaceutical company focused on developing meaningful therapies for patients with unmet medical needs in diseases that have seen limited therapeutic...
From
GlobeNewswire News Releases
Atara Biotherapeutics Announces Third Quarter 2015 Financial Results
November 05, 2015
Atara Biotherapeutics, Inc. (Nasdaq:ATRA), a biopharmaceutical company focused on developing meaningful therapies for patients with unmet medical needs in diseases that have seen limited therapeutic...
From
GlobeNewswire News Releases
Atara Bio’s Collaborating Investigators to Present Data From Two Cellular Therapy Product Candidates at the American Society of Hematology (ASH) Annual Meeting 2015
November 05, 2015
Presentations Include Clinical and Preclinical Results in Oncology and Virus-Associated Diseases
From
GlobeNewswire News Releases
Atara Biotherapeutics Announces Participation in Three Investor Conferences
October 29, 2015
Atara Biotherapeutics, Inc. (Nasdaq:ATRA), a biopharmaceutical company with a focus on developing meaningful therapies for patients with unmet medical needs in diseases that have seen limited...
From
GlobeNewswire News Releases
Atara Biotherapeutics and QIMR Berghofer Medical Research Institute Announce Exclusive License and Research Agreements
October 20, 2015
Atara Bio Complements Its Cytotoxic T-Cell Programs to Develop Potential Additional Treatments for Certain Cancers and Autoimmune Disorders
From
GlobeNewswire News Releases
Atara Bio Receives FDA Orphan Drug Designation for STM 434, Atara Bio's Activin Inhibitor for Ovarian Cancer
October 19, 2015
Atara Biotherapeutics, Inc. (Nasdaq:ATRA), a biopharmaceutical company with a focus on developing meaningful therapies for patients with unmet medical needs in diseases that have seen limited...
From
GlobeNewswire News Releases
Atara Bio to Host Investor Day on October 21, 2015
October 13, 2015
Atara Biotherapeutics, Inc., (Nasdaq:ATRA), today announced that the Company will host a live webcast in conjunction with its Investor Day on Wednesday, October 21, 2015 at 12:00p.m. ET in New York,...
From
GlobeNewswire News Releases
Atara Bio’s PINTA 745 Improves Insulin Sensitivity and Alters Fat Metabolism in Mice Fed With a High Fat Diet
October 05, 2015
Preclinical Data Published in the International Journal of Obesity
From
GlobeNewswire News Releases
Atara Bio’s Collaborating Investigators to Present Data at the American Society of Nephrology Kidney Week 2015
October 04, 2015
Atara Biotherapeutics, Inc. (Nasdaq:ATRA), a biopharmaceutical company with a focus on developing innovative therapies for patients with debilitating diseases, today announced that its collaborating...
From
GlobeNewswire News Releases
Atara Bio's T-Cell Product Candidate Activated Against Wilms' Tumor 1 Protein Demonstrates Encouraging Results in Patients With Plasma Cell Leukemia
September 23, 2015
Data Presented at the 15th International Myeloma Workshop
From
GlobeNewswire News Releases
Atara Biotherapeutics, Inc. to Present at Upcoming Investor Conferences in September 2015
September 02, 2015
From
GlobeNewswire News Releases
Atara Biotherapeutics Announces Completion of Enrollment in PINTA 745 Phase 2 Clinical Trial in End-Stage Renal Disease Patients With Protein Energy Wasting
August 30, 2015
Preliminary Top-Line Data Expected by the End of the Fourth Quarter of 2015
From
GlobeNewswire News Releases
Atara Biotherapeutics Announces Second Quarter 2015 Results
August 05, 2015
From
GlobeNewswire News Releases
Atara Bio Announces Closing of Underwritten Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares
July 15, 2015
From
GlobeNewswire News Releases
Atara Bio Announces Pricing of Its $180.0 Million Offering of Common Stock
July 09, 2015
From
GlobeNewswire News Releases
Atara Bio Announces Proposed Offering of Common Stock
July 07, 2015
From
GlobeNewswire News Releases
Critical Alerts For Juno Therapeutics Inc, Cigna, Atara Biotherapeutics, TASER International and Halliburton Released By InvestorsObserver
June 16, 2015
From
PR Newswire
Atara Biotherapeutics Exercises Exclusive License to T-Cell Technology From Memorial Sloan Kettering Cancer Center
June 14, 2015
Activated T-Cell Technology Designed to Harness Immune System to Fight Cancer and Infectious Disease
From
GlobeNewswire News Releases
Atara Biotherapeutics, Inc. to Present at Upcoming Investor Conferences in June 2015
May 26, 2015
From
GlobeNewswire News Releases
Update: Atara Biotherapeutics' Collaborating Investigators to Present Data at the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting
May 19, 2015
Atara Biotherapeutics' Collaborating Investigators to Present Clinical Data on T-Cell Therapy for EBV+ Lymphoma after Hematopoietic and Solid Organ Allografts at the 2015 American Society of Clinical...
From
GlobeNewswire News Releases
< Previous
1
2
3
4
5
6
7
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.